Interventions to Enhance Medication Persistence & Compliance in Patients

Status Completed

Clinical Trial Summary

Study Objectives: To explore the effectiveness of adjunctive intervention to enhance the medication compliance and persistence in patients with Overactive Bladder (OAB), thereby to improve treatment outcomes

Study Hypothesis: Health Education Intervention (HEI) can enhance the medication compliance and persistence, thereby can improve the treatment outcomes in conjunction with pharmacological therapy in OAB patients

Study Design: 6-month, randomized, open-label, multi-center trial at 13 university hospitals

Clinical Trial Description

Treatment - Fesoterodine (Toviaz) 4 or 8mg

Interventions (2 arms)

- Arm 1: No intervention

Patients in this arm will not be given HEI in conjunction with pharmacotherapy (Toviaz) which was developed for this trial.

- Arm 2: Health education intervention (HEI)

HEI will be performed by trained study coordinators with the leaflet designed for this trial composed of 4 parts.

1. Part 1: Understanding OAB Physiology of bladder Definition, symptom and prevalence of OAB OAB in a treatable condition. There are many options that may help your symptoms. Lifestyle change Medications Bladder training Pelvic floor muscle exercise

2. Part 2: Behavioral/lifestyle modification Modification of dietary habits Limit bladder irritants- caffeine (coffee, tea, coke...), juice, chemical flavors, spicy food. etc. Altering fluid intake Weight management Learn how weight can affect their condition Stop smoking Constipation management

3. Part 3: Bladder training Timed voiding- Goal is urinating every 3 or 4 hours during the day without fear of wetting accidents.

Urgency suppression Pelvic muscle contraction, count backwards from 100 by 7seconds, etc Pelvic floor muscle exercise Contraction (fast and slow) and relax the muscle for a count of 3. Repeat the fast and slow contractions 10 - 15 times. Do those at least 3 times a day.

4. Part 4: Understanding antimuscarinics How the medicine works How to take it Tips that may help manage side effects- dry mouth, constipation Therapy expectations

5. HEI include 3-day voiding diary for self tracking method. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01515722
Study type	Interventional
Source	Samsung Medical Center
Contact
Status	Completed
Phase	N/A
Start date	December 2010
Completion date	June 2012

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04578899` - "The Effectiveness of Transvertebral Magnetic Neuromodulation in Patients With Detrusor Overactivity"	N/A
Active, not recruiting	`NCT03556891` - Pivotal Study of eCoin for Overactive Bladder With Urgency Urinary Incontinence	N/A
Not yet recruiting	`NCT05977634` - Transcutaneous Tibial Nerve Stimulation for Idiopathic Overactive Bladder	N/A
Completed	`NCT01955408` - Severity of Overactive Bladder Symptoms in Patients After Synergo Treatment	N/A
Recruiting	`NCT06201013` - Efficacy and Safety of Vitamin D in the Treatment of OAB-wet in Children	N/A
Recruiting	`NCT03727711` - TPTNS: Home vs Hospital Treatment for Overactive Bladder	N/A
Completed	`NCT00768521` - A Study to Test the Effects of Tolterodine Tartrate in Patients With Overactive Bladder (0000-107)	Phase 1
Completed	`NCT03625843` - Mindfulness Exercises to Reduce Anxiety and Pain During Urodynamic Testing	N/A
Completed	`NCT02211846` - A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Mirabegron OCAS (Oral Controlled Absorption System) in Pediatric Subjects With Neurogenic Detrusor Overactivity or Overactive Bladder	Phase 1
Completed	`NCT02857816` - PRospective Study to Evaluate EffectivenesS With the NURO™ PErcutaneous Tibial Neuromodulation System in Patients With OAB	N/A
Completed	`NCT02835846` - Investigation of the Effect of the Female Urinary Microbiome on Incontinence	Phase 4
Withdrawn	`NCT02320201` - Foot Neuromodulation for Overactive Bladder in Children	N/A
Completed	`NCT02202031` - Controlling Urgency Through Relaxation Exercises	N/A
Completed	`NCT01458197` - A Phase 2 Study to Compare the Efficacy and Tolerability of Tarafenacin 0.2 mg and Tarafenacin 0.4 mg to Placebo in Patients Suffering From Overactive Bladder.	Phase 2
Completed	`NCT01437670` - Observational Study to Estimate the Dry Mouth in OAB Patients With Solifenacin	N/A
Not yet recruiting	`NCT01409512` - Evaluation of Autonomic System Before and After Anticholinergic Treatment in Women With Overactive Bladder	N/A
Not yet recruiting	`NCT01423838` - Comparison of Solifenacin and Oxybutynin in the Treatment of Overactive Bladder	Phase 4
Terminated	`NCT01758848` - Physical Therapy for Overactive Bladder	N/A
Withdrawn	`NCT01210859` - Effects of Antimuscarinic Drugs on Overactive Bladder (OAB) Symptoms After Insertion of Ureteral Stents	N/A
Completed	`NCT01122550` - Reproducibility Study of Overactive Bladder Symptom Score [OABSS]	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Interventions to Enhance Medication Persistence and Compliance in Patients With Overactive Bladder

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms